Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Coffman

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
The Journal of Experimental Medicine|March 6, 2002
In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokinesFranck J Barrat, Daniel J Cua, André Boonstra, et al.
The Journal of Experimental Medicine|November 27, 2013
RNA recognition by human TLR8 can lead to autoimmune inflammationCristiana Guiducci, Mei Gong, Alma-Martina Cepika, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 11, 2003
Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupusKarl Balabanian, Jacques Couderc, Laurence Bouchet-Delbos, et al.
Thorax|January 28, 2014
A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in miceJohn D Campbell, Sariah A Kell, Heather M Kozy, et al.
Science Translational Medicine|March 11, 2011
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosusGina S Garcia-Romo, Simone Caielli, Barbara Vega, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung CancerEdward B Garon, Alexander I Spira, Melissa Johnson, et al.
Nature|June 19, 2010
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupusCristiana Guiducci, Mei Gong, Zhaohui Xu, et al.
Cancer Discovery|August 30, 2018
<i>In Situ</i> Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent LymphomaMatthew J Frank, Patrick M Reagan, Nancy L Bartlett, et al.
The Journal of Clinical Investigation|September 4, 2009
CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humansJohn D Campbell, Yan Cho, Martyn L Foster, et al.
Clinical Pharmacology and Therapeutics|November 15, 2017
First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-ToleratedSam Jackson, Albert F Candia, Stephen Delaney, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
The Journal of Experimental Medicine|March 6, 2002
In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokinesFranck J Barrat, Daniel J Cua, André Boonstra, et al.
The Journal of Experimental Medicine|November 27, 2013
RNA recognition by human TLR8 can lead to autoimmune inflammationCristiana Guiducci, Mei Gong, Alma-Martina Cepika, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 11, 2003
Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupusKarl Balabanian, Jacques Couderc, Laurence Bouchet-Delbos, et al.
Thorax|January 28, 2014
A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in miceJohn D Campbell, Sariah A Kell, Heather M Kozy, et al.
Science Translational Medicine|March 11, 2011
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosusGina S Garcia-Romo, Simone Caielli, Barbara Vega, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung CancerEdward B Garon, Alexander I Spira, Melissa Johnson, et al.
Nature|June 19, 2010
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupusCristiana Guiducci, Mei Gong, Zhaohui Xu, et al.
Cancer Discovery|August 30, 2018
<i>In Situ</i> Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent LymphomaMatthew J Frank, Patrick M Reagan, Nancy L Bartlett, et al.
The Journal of Clinical Investigation|September 4, 2009
CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humansJohn D Campbell, Yan Cho, Martyn L Foster, et al.
Clinical Pharmacology and Therapeutics|November 15, 2017
First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-ToleratedSam Jackson, Albert F Candia, Stephen Delaney, et al.
Pageof 7